CL2024001833A1 - Composiciones y métodos para la prevención de la miocarditis piscina - Google Patents

Composiciones y métodos para la prevención de la miocarditis piscina

Info

Publication number
CL2024001833A1
CL2024001833A1 CL2024001833A CL2024001833A CL2024001833A1 CL 2024001833 A1 CL2024001833 A1 CL 2024001833A1 CL 2024001833 A CL2024001833 A CL 2024001833A CL 2024001833 A CL2024001833 A CL 2024001833A CL 2024001833 A1 CL2024001833 A1 CL 2024001833A1
Authority
CL
Chile
Prior art keywords
pool
myocarditis
prevention
compositions
methods
Prior art date
Application number
CL2024001833A
Other languages
English (en)
Spanish (es)
Inventor
Haugland Oyvind
Andre De Feijter Karlsen Marius
Helena Hauge Linda
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CL2024001833A1 publication Critical patent/CL2024001833A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024001833A 2021-12-20 2024-06-18 Composiciones y métodos para la prevención de la miocarditis piscina CL2024001833A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163291577P 2021-12-20 2021-12-20

Publications (1)

Publication Number Publication Date
CL2024001833A1 true CL2024001833A1 (es) 2024-10-18

Family

ID=85173073

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001833A CL2024001833A1 (es) 2021-12-20 2024-06-18 Composiciones y métodos para la prevención de la miocarditis piscina

Country Status (8)

Country Link
US (1) US20250127873A1 (cg-RX-API-DMAC7.html)
EP (1) EP4453008A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025503468A (cg-RX-API-DMAC7.html)
CN (1) CN118434755A (cg-RX-API-DMAC7.html)
CA (1) CA3242834A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001833A1 (cg-RX-API-DMAC7.html)
DK (1) DK202470172A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023122525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021335500A1 (en) 2020-09-04 2023-05-04 Elanco Us Inc. Palatable formulations
EP4453008A1 (en) 2021-12-20 2024-10-30 Zoetis Services LLC Compositions and methods for prevention of piscine myocarditis
DK202370610A1 (en) * 2022-12-13 2024-07-12 Zoetis Services Llc Methods of vaccine administration to salmonids
WO2026162707A1 (en) 2025-01-31 2026-08-06 Intervet International B.V. Piscine myocarditis virus vaccine
CN120393054B (zh) * 2025-04-21 2026-01-27 华南农业大学 一种核酸递送载体、递送系统及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2650730A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
DK179920B1 (en) * 2010-04-21 2019-10-07 Pharmaq As Nucleic acid sequences of a fish virus and its use
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
GB201415789D0 (en) 2014-09-05 2014-10-22 Touchlight Genetics Ltd Synthesis of DNA
US10456459B2 (en) 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
CN116732145A (zh) 2016-08-16 2023-09-12 塔驰莱特Ip有限公司 闭合线性dna的生产
GB2559193A (en) * 2017-01-31 2018-08-01 Pharmaq As Virus-like particle
WO2018224516A1 (en) * 2017-06-06 2018-12-13 Fish Vet Group Norge As Detection and treatment of pmcv infection in cleaner fish
GB201805683D0 (en) 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
GB202002068D0 (en) 2020-02-14 2020-04-01 Touchlight Ip Ltd DNA synthesis yield improvements
EP4453008A1 (en) 2021-12-20 2024-10-30 Zoetis Services LLC Compositions and methods for prevention of piscine myocarditis

Also Published As

Publication number Publication date
CA3242834A1 (en) 2023-06-29
DK202470172A1 (en) 2024-07-12
JP2025503468A (ja) 2025-02-04
CN118434755A (zh) 2024-08-02
US20250127873A1 (en) 2025-04-24
EP4453008A1 (en) 2024-10-30
WO2023122525A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
CL2024001582A1 (es) Compuestos terapéuticos para la infección por el virus vih
MX2022011671A (es) Vacunas contra el coronavirus y metodos de uso.
CL2019000415A1 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéuticos de una infección por el virus del vih.
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
CR20150454A (es) Compuestos amida para el tratamiento de vih
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
MX2023013140A (es) Vacunas contra el virus de la hepatitis b.
ZA202207169B (en) Methods, compositions, and vaccines for treating a virus infection
CL2021003388A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
BR112017022544A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?.
BR112017022605A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?.
CL2021002799A1 (es) Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
MX2019000725A (es) Composiciones de vacuna para tratamiento de virus zika.
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
MX2022009176A (es) Metodo y composiciones para el tratamiento de infeccion por coronavirus.
ECSP20056232A (es) Régimen posológico del modulador del ensamblaje de la cápside
MX2021004859A (es) Vacuna de ibv h52 con proteina espicular heterologa.
CL2024003287A1 (es) Virus para vacuna contra el síndrome respiratorio y reproductivo porcino.
CO2020000021A2 (es) Método para preparar reserva de cepas víricas de trabajo para la influenza, método para preparar la vacuna contra la influenza usando la misma reserva de cepas, y la reserva de cepas víricas preparadas por el mismo método
MX2019001412A (es) Compuestos de 9-aminometil minociclina y usos de los mismos.
AR056733A1 (es) Uso de vacunas para el tratamiento / prevencion de la transmision de patogenos
MX2021013609A (es) Materiales y métodos para tratar la degeneración macular relacionada con la edad.
CL2009000287A1 (es) Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.
MX2018009543A (es) Metodo para tratar la infección por el virus del zika con composiciones que contienen quercetina.